315 related articles for article (PubMed ID: 31820210)
1. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.
Ushigome M; Shimada H; Miura Y; Yoshida K; Kaneko T; Koda T; Nagashima Y; Suzuki T; Kagami S; Funahashi K
Int J Clin Oncol; 2020 Apr; 25(4):622-632. PubMed ID: 31820210
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
3. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.
Yang XQ; Li Y; Chen C; Peng CW; Liu SP; Liu Y
Med Oncol; 2011 Sep; 28(3):789-95. PubMed ID: 20373053
[TBL] [Abstract][Full Text] [Related]
4. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
5. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer.
Takakura Y; Ikeda S; Imaoka Y; Urushihara T; Itamoto T
Colorectal Dis; 2015 May; 17(5):417-25. PubMed ID: 25512077
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
[TBL] [Abstract][Full Text] [Related]
7. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
Anticancer Res; 2014 Jul; 34(7):3753-8. PubMed ID: 24982398
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer.
Zheng CX; Zhan WH; Zhao JZ; Zheng D; Wang DP; He YL; Zheng ZQ
World J Gastroenterol; 2001 Jun; 7(3):431-4. PubMed ID: 11819806
[No Abstract] [Full Text] [Related]
9. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
10. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
Morita S; Nomura T; Fukushima Y; Morimoto T; Hiraoka N; Shibata N
Dis Colon Rectum; 2004 Feb; 47(2):227-32. PubMed ID: 15043294
[TBL] [Abstract][Full Text] [Related]
11. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
12. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
13. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
[TBL] [Abstract][Full Text] [Related]
14. Time-dependency of the prognostic effect of carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma.
Diez M; Pollan M; Müguerza JM; Gaspar MJ; Duce AM; Alvarez MJ; Ratia T; Herñandez P; Ruiz A; Granell J
Cancer; 2000 Jan; 88(1):35-41. PubMed ID: 10618603
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Value of Preoperative Serum CEA and CA19-9 Values in Stage I-III Colorectal Cancer.
Wang RF; Song BR; Peng JJ; Cai GX; Liu FQ; Wang MH; Cai SJ; Ye X
Hepatogastroenterology; 2014 Jun; 61(132):994-9. PubMed ID: 26158155
[TBL] [Abstract][Full Text] [Related]
16. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
[TBL] [Abstract][Full Text] [Related]
17. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.
Park IJ; Choi GS; Jun SH
Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer.
Gong X; Zhang H
J Clin Lab Anal; 2020 Jul; 34(7):e23268. PubMed ID: 32118318
[TBL] [Abstract][Full Text] [Related]
20. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
